Dr. Lisa G. Roth Takes the Helm at Pediatric Hematology-Oncology Division at NYU Langone
Dr. Lisa G. Roth, a well-known pediatric oncologist and lymphoma survivor, has taken on the role of Director of the Division of Pediatric Hematology-Oncology at Hassenfeld Children's Hospital at NYU Langone. She is not just an accomplished physician; her journey through cancer as a patient gives her unique insight into the emotional and physical challenges faced by her young patients and their families.
Having returned to NYU Langone Health, where she once graduated from medical school, Dr. Roth previously honed her expertise at Weill Cornell Medicine and NewYork-Presbyterian Hospital. At these institutions, she provided care for children and young adults battling cancers while leading research focused on lymphomas that predominantly affect younger demographics.
"My own experience as a patient was crucial; it underscored the need to treat not just the disease, but the whole person," Dr. Roth shared, reflecting her comprehensive approach to care. Her commitment to holistic treatment is set to shape the future of pediatric hematology-oncology at the facility.
Dr. Roth specializes in various types of lymphomas, including Hodgkin lymphoma and rarer forms of cancer that impact younger individuals. Her research, supported by the National Institutes of Health, aims to delve deeper into how these malignancies develop at the molecular level, with the overarching goal of unveiling more effective, targeted treatments. Additionally, she has played a vital role in national clinical trials, striving to improve treatment protocols and outcomes for pediatric patients.
As Director, Dr. Roth will oversee clinical care, pioneering research, and educational programs within her division. She aims to enhance accessibility to cutting-edge therapies and clinical trials for young cancer patients. Dr. Roth will be treating her patients at the Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, recognized as one of the top facilities in the nation for treating childhood cancer.
Working alongside her colleague Dr. Gabriel A. Robbins, Medical Director of the center, Dr. Roth aims to promote a cohesive approach to multi-disciplinary care, thereby advancing research on pediatric treatments.
Dr. Roth's return to NYU Langone is a significant milestone not only for her career but also for the health system’s commitment to providing compassionate, patient-centered care. "I am honored to rejoin NYU Langone and collaborate with an exceptional team dedicated to refining research and providing emotional support to children and their families during these challenging times," she emphasized.
An alumni of the NYU Grossman School of Medicine, Dr. Roth completed her residency and fellowship at leading institutions, including Weill Cornell and Memorial Sloan Kettering Cancer Center. She has held influential positions, including vice chair within the Children's Oncology Group focusing on Hodgkin Lymphoma.
Dr. Roth's appointment succeeds Dr. Elizabeth A. Raetz, who directed the division for eight years and is now taking on the role of Vice Chair for Clinical Affairs in the Department of Pediatrics. Dr. Raetz is known for her dedication to advancing clinical trials in childhood malignancies, enhancing treatment protocols through rigorous research and compassionate care.
Dr. Arun Chopra, Interim Chair of the Department of Pediatrics, shared, "We are ecstatic to welcome Dr. Roth back to NYU Langone. Her expertise and innovative approach will undoubtedly enhance our division's mission to push the boundaries of pediatric cancer research while ensuring meticulous care for our patients."
In summary, Dr. Roth’s leadership is anticipated to drive significant advancements in pediatric oncology, prioritizing innovative research and comprehensive care tailored to the unique needs of children and adolescents battling cancer. As both an expert in her field and a survivor, her perspective is likely to foster an environment of hope, healing, and breakthrough treatment protocols that can change lives for the better.
Having returned to NYU Langone Health, where she once graduated from medical school, Dr. Roth previously honed her expertise at Weill Cornell Medicine and NewYork-Presbyterian Hospital. At these institutions, she provided care for children and young adults battling cancers while leading research focused on lymphomas that predominantly affect younger demographics.
"My own experience as a patient was crucial; it underscored the need to treat not just the disease, but the whole person," Dr. Roth shared, reflecting her comprehensive approach to care. Her commitment to holistic treatment is set to shape the future of pediatric hematology-oncology at the facility.
Dr. Roth specializes in various types of lymphomas, including Hodgkin lymphoma and rarer forms of cancer that impact younger individuals. Her research, supported by the National Institutes of Health, aims to delve deeper into how these malignancies develop at the molecular level, with the overarching goal of unveiling more effective, targeted treatments. Additionally, she has played a vital role in national clinical trials, striving to improve treatment protocols and outcomes for pediatric patients.
As Director, Dr. Roth will oversee clinical care, pioneering research, and educational programs within her division. She aims to enhance accessibility to cutting-edge therapies and clinical trials for young cancer patients. Dr. Roth will be treating her patients at the Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, recognized as one of the top facilities in the nation for treating childhood cancer.
Working alongside her colleague Dr. Gabriel A. Robbins, Medical Director of the center, Dr. Roth aims to promote a cohesive approach to multi-disciplinary care, thereby advancing research on pediatric treatments.
Dr. Roth's return to NYU Langone is a significant milestone not only for her career but also for the health system’s commitment to providing compassionate, patient-centered care. "I am honored to rejoin NYU Langone and collaborate with an exceptional team dedicated to refining research and providing emotional support to children and their families during these challenging times," she emphasized.
An alumni of the NYU Grossman School of Medicine, Dr. Roth completed her residency and fellowship at leading institutions, including Weill Cornell and Memorial Sloan Kettering Cancer Center. She has held influential positions, including vice chair within the Children's Oncology Group focusing on Hodgkin Lymphoma.
Dr. Roth's appointment succeeds Dr. Elizabeth A. Raetz, who directed the division for eight years and is now taking on the role of Vice Chair for Clinical Affairs in the Department of Pediatrics. Dr. Raetz is known for her dedication to advancing clinical trials in childhood malignancies, enhancing treatment protocols through rigorous research and compassionate care.
Dr. Arun Chopra, Interim Chair of the Department of Pediatrics, shared, "We are ecstatic to welcome Dr. Roth back to NYU Langone. Her expertise and innovative approach will undoubtedly enhance our division's mission to push the boundaries of pediatric cancer research while ensuring meticulous care for our patients."
In summary, Dr. Roth’s leadership is anticipated to drive significant advancements in pediatric oncology, prioritizing innovative research and comprehensive care tailored to the unique needs of children and adolescents battling cancer. As both an expert in her field and a survivor, her perspective is likely to foster an environment of hope, healing, and breakthrough treatment protocols that can change lives for the better.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.